Jpmorgan Chase & CO Pliant Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 49,190 shares of PLRX stock, worth $712,763. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,190

Previous 58,328 15.67%

Holding current value

$712,763

Previous $869,000 39.24%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$10.58 - $15.61 $96,680 - $142,644	-9,138 Reduced 15.67%	49,190 $528,000
Q1 2024 May 10, 2024	SELL	$14.14 - $19.59 $385,527 - $534,121	-27,265 Reduced 31.85%	58,328 $869,000
Q4 2023 Feb 12, 2024	BUY	$12.85 - $19.15 $48,148 - $71,755	3,747 Added 4.58%	85,593 $1.55 Million
Q3 2023 Nov 14, 2023	BUY	$14.58 - $20.15 $126,102 - $174,277	8,649 Added 11.82%	81,846 $1.42 Million
Q2 2023 Aug 11, 2023	BUY	$18.12 - $30.56 $941,696 - $1.59 Million	51,970 Added 244.83%	73,197 $1.33 Million
Q1 2023 May 18, 2023	BUY	$18.73 - $36.26 $387,486 - $750,146	20,688 Added 3838.22%	21,227 $564,000
Q1 2023 May 11, 2023	SELL	$18.73 - $36.26 $270,086 - $522,869	-14,420 Reduced 96.4%	539 $14,000
Q4 2022 Feb 13, 2023	SELL	$17.0 - $25.43 $374,204 - $559,765	-22,012 Reduced 59.54%	14,959 $290,000
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $271,402 - $857,378	35,385 Added 2231.08%	36,971 $772,000
Q2 2022 Aug 11, 2022	SELL	$4.11 - $8.75 $58,234 - $123,978	-14,169 Reduced 89.93%	1,586 $13,000
Q1 2022 May 11, 2022	SELL	$7.01 - $14.1 $266,947 - $536,942	-38,081 Reduced 70.74%	15,755 $110,000
Q4 2021 Feb 10, 2022	BUY	$12.27 - $18.26 $457,278 - $680,513	37,268 Added 224.94%	53,836 $727,000
Q3 2021 Nov 12, 2021	BUY	$16.48 - $28.98 $273,040 - $480,140	16,568 New	16,568 $280,000

Others Institutions Holding PLRX

# of Institutions

163

Shares Held

63.9M

Call Options Held

481K

Put Options Held

105K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $705M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Pliant Therapeutics, Inc. Transaction History